Proactive clinical Review of patients taking Opioid Medicines long-term for persistent Pain led by clinical Pharmacists in primary care Teams 

Promppt logo


PROMPPT is a 5-year research programme, launched in March 2019.

Year 1 started with the Q-PROMPPT study that aimed to find out about patients, clinical pharmacists and GPs’ experiences and views on:

  • Using regular medication, particularly opioids, for long-term pain
  • How pain medicines are currently managed and how they could be reviewed in future
  • The idea of clinical pharmacists in GP surgeries reviewing patients on regular opioids
  • What would make a pain medicines review relevant, useful and appealing to patients, clinical pharmacists and GPs

Next, a study of 80 patients will test how well clinical pharmacists deliver PROMPPT, whether it is acceptable and practical to deliver, and what proportion of patients agree to take part. The research team will make improvements based on the results (PROMPPT-FS).

Finally, a full-scale trial with over 1000 patients will test whether delivering PROMPPT in GP practices leads to less opioid use, without making pain or pain interference worse, and whether this results in better use of NHS resources compared to usual GP care (PROMPPT).

Chief Investigator: Professor Christian Mallen 
Associate Investigator: Dr Julie Ashworth
Trial Manager: Gemma Hughes 
Sponsor / reference number: Keele University / TBC
Funder / reference number: National Institute for Health Research (NIHR)/
Start date: 1 Jan 2019
End date:  31 Dec 2023

Study design

Cluster Randomised Controlled Trial with internal pilot and linked health economic evaluation and mixed methods process evaluation.

Aim and objectives

To investigate the clinical effectiveness and cost-effectiveness of providing the PROMPPT intervention (practice pharmacist-led primary care pain review) to patients with persistent pain who are prescribed long-term opioids compared to usual primary care.